ADMA Biologics shares hit record high after FDA approves plasma yield process

Shares of ADMA Biologics ADMA.O hit a record high on Mon after the biopharmaceutical company won FDA approval for its plasma yield enhancement production process

ADMA rose to as high as $25.67, highest level on record, and on track for the highest daily pct gain since Nov last year

ADMA's process demonstrated an ability to increase production yields by approximately 20% from the same starting plasma volume

"This approval represents a pivotal milestone for ADMA, unlocking the opportunity for meaningful acceleration in our revenue and earnings trajectory beginning in late 2025 and accelerating further into 2026 and beyond," said ADMA CEO Adam Grossman in a statement

Among the 4 analysts that cover ADMA, the breakdown of recommendations are 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell"

ADMA is up 45% YTD versus 0.53% gain in the S&P 500 health index .SPXHC